Specialty Pharmacy

AbbVie announced positive top-line results from a phase 3 trial for the efficacy and safety of upadacitinib for individuals with the rheumatic disease.

The medication, which has been cleared as a treatment for the inflammatory disease of the throat, is under priority review by the agency.

The majority of treatment-related adverse events (TRAEs) were grade 1-2 in severity, and no patients experienced dose-limiting toxicities during the 28 days following initial treatment.

Allostatic load is caused by a number of different stressors, including social isolation, poverty, and racism, many of which are commonly experienced by individuals belonging to racial and ethnic minorities, according to the investigators.

Winners were announced and celebrated at the Next-Generation Pharmacist® of the Year gala on Oct. 8 at Founders Hall in Charlotte, N.C.

There is a real opportunity for technology to alleviate some of the administrative burdens pharmacists face so that they have more time to focus on patient care.

Cemiplimab is a recombinant human immunoglobulin G4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

As practices have gained experience in the post-COVID-19 environment, health care professionals have found innovative ways to work around many of the obstacles the pandemic presents.

Medication adherence, diet, and exercise are each critical components in caring for patients with a chronic illness, but each is difficult to be managed by physicians alone.

Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what oncologic emergencies are and how they are classified.

Soliman is ecstatic to celebrate the 4th annual #WomenPharmacistDay and that the pharmacy landscape is continuing to recognize the contributions of women in the field.

New legislation in New York state seeks to address flaws in prescription drug distribution system.

Nusinersen (Spinraza) is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Respiratory infections can become a problem in muscular dystrophy, therefore immunizations for pneumonia and influenza are vital.

Isatuximab-irfc (Sarclisa; sanofi-aventis) provides patients with another option for treatment and significantly reduces the risk of disease progression or death.

Growing demand for specialty care, shifting prescriber habits, and new reimbursement models have forced stakeholders to adjust practices to optimize patient outcomes.

The objective of this study was to evaluate the safety and immunogenicity of the live attenuated zoster vaccine (ZVL) in patients receiving TNFis, according to the study authors.

Glatiramer acetate modifies immune processes that are believed to be responsible for the pathogenesis of multiple sclerosis.

Prescribers, pharmacists, nurses, lab technicians, and other health care professionals must work as a team to create awareness and understanding of pharmacogenomics integration.

According to a press release from Mirum, maralixibat is the first and only FDA-approved medication to treat ALGS, a rare liver disease that affects 2000 to 2500 children in the United States.

Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer.

Pharmacy Times will be celebrating pharmacists throughout the month of October to recognize their contributions to the health care field.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what the role of the pharmacist is during the treatment of patients with advanced cutaneous T cell lymphoma.

Although specialty pharmacies may be able to offer some of the services that a hub provider does, a hub can standardize patient and provider support across the network.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

Cemiplimab-rwlc is being developed by Regeneron and Sanofi under a global collaboration agreement.

Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.

The combination maintained superior OS and response benefits versus sunitinib in both patients with intermediate- and poor-risk prognostic factors, the primary endpoint population, and across all randomized patients.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, describes some of the challenges providers face during the treatment of patients with advanced cutaneous T cell lymphoma and how to address them.